Search

Search Constraints

You searched for: Author/Creator Streffer, Johannes

Search Results

1. [F1–02–02]: DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER'S DISEASE PATHOLOGY AND PROGRESSION. (1st July 2017)

2. [P1–289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF Aβ OR AMYLOID‐PET) IN THE EMIF‐AD BIOMARKER DISCOVERY COHORT. (1st July 2017)

3. [P2–211]: AMYLOID‐β42 (Aβ42) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOID‐POSITIVE VERSUS AMYLOID‐NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC AT‐RISK FOR AD POPULATION. (1st July 2017)

4. [P2–212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER's DISEASE (EMIF‐AD): THE BIOMARKER DISCOVERY STUDY. (1st July 2017)

5. [P4–158]: PRE‐SCREENING FOR EPISODIC MEMORY DEFICITS CAN ENRICH FOR ELIGIBLE SUBJECTS IN EARLY ALZHEIMER's DISEASE CLINICAL TRIALS. (1st July 2017)

6. A metabolite‐based machine learning approach to diagnose Alzheimer‐type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. Issue 1 (1st January 2019)

7. Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls. Issue 1 (28th April 2014)

8. ACI‐24 in adults with Down syndrome: Results of a phase 1b, randomized, placebo‐controlled study. (31st December 2021)

9. ACI‐24 in adults with Down syndrome: Results of a phase 1b, randomized, placebo‐controlled study. (31st December 2021)

10. Assessment of cognitive‐driven activity of daily living impairment in non‐demented Parkinson's patients. Issue 1 (15th October 2018)